Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Bryce Elkins who wrote (18792)	4/7/1998 1:02:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

ble, I would be surprised to see LGND return to $12. There is quite a bit of good news scheduled and eventually even the street can "read between the lines" of the recent news on breast cancer prevention. The modest success by Tamoxifen is definitely a "proof of principle" for chemoprevention. If you saw the NCI press conference, it would be hard to miss the take home message. The follow-up trial (Tamoxifen vs Evista) was set to begin almost immediately and interim data will come in just in time for the Targretin challenge (Targretin vs whoever wins the Tamoxifen/Evista match-up). Future treatment and prevention approaches will use combination therapies and LGND has almost all of the bases covered.